Observing the progression of axial spondyloarthritis in Chinese patients
The Disease Progression of Chinese Axial Spondyloarthritis in a Real-word Cohort Study
This study looks at how axial spondyloarthritis changes over time in Chinese adults to better understand the disease and its effects.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 2250 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | China-Japan Friendship Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT06844643 on ClinicalTrials.gov |
What this trial studies
This observational cohort study aims to understand the disease progression of axial spondyloarthritis (axSpA) in Chinese patients aged 18 and older. Participants will be followed at 4-6 month intervals, with data collected at baseline and during follow-up visits. The primary outcomes include structural damage assessed through imaging techniques and disease activity measured by established scales. Secondary outcomes will focus on inflammatory markers and functional indices related to the disease.
Who should consider this trial
Good fit: Ideal candidates for this study are Chinese patients aged 18 years or older diagnosed with axial spondyloarthritis.
Not a fit: Patients with serious comorbid conditions or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the progression of axial spondyloarthritis, leading to improved management strategies for patients.
How similar studies have performed: While there have been studies on axial spondyloarthritis, this specific observational approach focusing on a Chinese cohort may provide novel insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 years or older * Diagnosis of axial spondyloarthritis (axSpA) according to the Assessment of Spondyloarthritis International Society (ASAS) classification criteria Exclusion Criteria: * Presence of severe, unstable medical conditions that may interfere with the study assessments, including but not limited to: End-stage renal disease (eGFR \< 30 mL/min/1.73m²) Severe cardiovascular disease Active malignancy or malignancy requiring ongoing treatment * Current diagnosis of schizophrenia, other psychotic disorders, severe cognitive impairment, or epilepsy with recurrent uncontrolled seizures, which, in the opinion of the investigator, may impair the ability to provide informed consent or comply with follow-up visits. * Pregnant or lactating women
Where this trial is running
Beijing
- China-Japan Friendship Hospital — Beijing, China (Recruiting)
Study contacts
- Study coordinator: weiping kong
- Email: kongweiping75@126.com
- Phone: 0086-10-13611038252
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.